Publication:
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash

dc.contributor.authorChantarangsu S.
dc.contributor.authorMushiroda T.
dc.contributor.authorMahasirimongkol S.
dc.contributor.authorKiertiburanakul S.
dc.contributor.authorSungkanuparph S.
dc.contributor.authorManosuthi W.
dc.contributor.authorTantisiriwat W.
dc.contributor.authorCharoenyingwattana A.
dc.contributor.authorSura T.
dc.contributor.authorTakahashi A.
dc.contributor.authorKubo M.
dc.contributor.authorKamatani N.
dc.contributor.authorChantratita W.
dc.contributor.authorNakamura Y.
dc.date.accessioned2021-04-05T03:35:08Z
dc.date.available2021-04-05T03:35:08Z
dc.date.issued2011
dc.date.issuedBE2554
dc.description.abstractBackground. We aimed to identify disease-predisposing variations with nevirapine-induced rash using genome-wide single-nucleotide polymorphisms (SNPs) as genetic markers. Methods. A genome-wide association study (GWAS) was performed using-550000 markers in 72 human immunodeficiency virus (HIV)-infected Thai patients with nevirapine-induced rash and 77 nevirapine-tolerant patients, and then candidate SNPs were further evaluated in a replication set (88 patients with nevirapine-induced rash and 145 nevirapine-tolerant patients). Results. The genome-wide association analysis and replication studies of candidate SNPs identified significant associations of nevirapine-induced rash with 2 SNPs (rs1265112 and rs746647) within CCHCR1 on chromosome 6p21.3 (P GWAS = 1.6 × 10 -4; P replication = 2.6 × 10 -5; P combined = 1.2 × 10 -8). The odds ratio (OR) of the risk genotypes under a dominant model was 4.36 (95% confidence interval [CI], 2.58-7.36). The noncoding SNPs rs1265112 and rs746647 were in complete linkage disequilibrium with the nonsynonymous SNP rs1576 (r 2 5 1.00), which has been associated with psoriasis. The logistic regression analysis also indicated genetic variations in CCHCR1 to be significantly associated with rash, with an OR of 2.59 (95% CI, 1.82-3.68; P = .007). The receiver operating characteristic curve showed that the algorithm had an area under the curve of 76.4%, which was developed with 5 factors: rs1576*G status, HLA-B*3505 status, not receiving prescribed lead-in of nevirapine, history of drug allergy, and CD4 cell count prior to the nevirapine treatment. Conclusions. We demonstrated that genetic variations in CCHCR1 are strongly associated with nevirapineinduced rash. A predictive model that includes genetic and clinical risk factors for nevirapine-associated rash might be useful in lowering the incidence of rash associated with nevirapine initiation among HIV-infected patients. © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationClinical Infectious Diseases. Vol 53, No.4 (2011), p.341-348
dc.identifier.doi10.1093/cid/cir403
dc.identifier.issn10584838
dc.identifier.other2-s2.0-79961219567
dc.identifier.urihttps://hdl.handle.net/20.500.14740/7265
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherCoiled coil alpha helical rod protein1
dc.subject.otherNevirapine
dc.subject.otherPeptides and proteins
dc.subject.otherUnclassified drug
dc.subject.otherCase control study
dc.subject.otherCD4 lymphocyte count
dc.subject.otherChromosome 6p
dc.subject.otherControlled study
dc.subject.otherDisease predisposition
dc.subject.otherDisease severity
dc.subject.otherDrug eruption
dc.subject.otherDrug hypersensitivity
dc.subject.otherDrug tolerance
dc.subject.otherGenetic association
dc.subject.otherGenetic variability
dc.subject.otherHuman
dc.subject.otherHuman immunodeficiency virus infected patient
dc.subject.otherHuman immunodeficiency virus infection
dc.subject.otherMajor clinical study
dc.subject.otherMedical history
dc.subject.otherNucleotide sequence
dc.subject.otherPriority journal
dc.subject.otherPsoriasis
dc.subject.otherRetrospective study
dc.subject.otherReview
dc.subject.otherSingle nucleotide polymorphism
dc.subject.otherThailand
dc.subject.otherAnti-HIV Agents
dc.subject.otherChromosomes, Human, Pair 6
dc.subject.otherDrug Eruptions
dc.subject.otherGenetic Predisposition to Disease
dc.subject.otherGenome-Wide Association Study
dc.subject.otherHIV Infections
dc.subject.otherHumans
dc.subject.otherIntracellular Signaling Peptides and Proteins
dc.subject.otherLamivudine
dc.subject.otherLogistic Models
dc.subject.otherNevirapine
dc.subject.otherPolymorphism, Single Nucleotide
dc.subject.otherRetrospective Studies
dc.subject.otherRisk Factors
dc.subject.otherROC Curve
dc.subject.otherStavudine
dc.subject.otherThailand
dc.titleGenome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79961219567&doi=10.1093%2fcid%2fcir403&partnerID=40&md5=0b64c693b382dfa274a5aee57deb8421

Files